To include your compound in the COVID-19 Resource Center, submit it here.

GSK preparing submissions for Nucala in COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) plans to submit regulatory applications this half for Nucala mepolizumab (SB-240563) to treat chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype after reporting mixed data from the double-blind, international Phase III METREX and METREO trials. The trials enrolled COPD patients at

Read the full 460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE